Yuan-Liang Wang
Head of Biology Discovery Department, Senior Scientist OBI Pharma Inc.
I am a molecular biologist and Senior Scientist at OBI Pharma with over 10 years of experience in oncology research and drug development. I lead early discovery initiatives that integrate target identification, antibody–drug conjugate (ADC) design, and advanced preclinical platforms—including patient-derived organoids (PDOs) and circulating tumor cell (CTC) assays—to dissect mechanisms of action and accelerate candidates toward IND-enabling studies.
My work focuses on bridging scientific innovation with rigorous translational validation to advance targeted therapies across multiple cancer types. I also provide strategic leadership within cross-functional project teams, mentor junior scientists, and ensure that discovery efforts are aligned with clinical development goals. My core expertise includes ADC design and translational validation, functional screening using 3D organoid and spheroid models, biomarker discovery through CTC analysis, and mechanistic studies to understand therapeutic response and resistance.
Seminars
- Physiologically relevant screening platform: Patient-derived organoids (PDOs) retain tumor complexity, offering more predictive ADC response than 2D or animal models
- Integrated target validation and cytotoxicity assessment: Concurrently evaluate antigen expression and ADC potency across cancer types
- Biomarker-driven patient stratification: Link PDOs response with molecular data to identify predictive markers and guide patient selection
